Katharine Dormandy Heamophilia Centre and Thrombosis Unit, Royal Free Hospital
Professor Amit C. Nathwani is a Senior NIHR Investigator and Professor of Haematology at UCL. He is the Founder and Chief Scientific Officer of Freeline Therapeutics, a company dedicated to developing curative therapeutics for systemic disorders. He graduated in Medicine from the University of Aberdeen in 1984. His PhD was on the regulation of the tissue factor gene. His landmark gene therapy trial was the first to show successful correction of bleeding diathesis in patients with severe haemophilia B, a programme. Recently Professor Nathwani’s novel gene therapy approach for Haemophilia A has been shown to normalise Factor VIII levels, a feat that was deemed impossible 10 years ago. Thus, Professor Nathwani’s gene therapy strategies for Haemophilia have evolved over time to generate functional cures in patients with inherited bleeding disorders.
Professor Nathwani is the recipient of several awards including the ESGCT Outstanding Achievement Award, Human Gene Therapy Blue Ribbon Panel award, and UCL Business Award.